Figure 3: Circulating concentration of (A) ALT (IU/L) and (B) K18 (U/L) for sequential samples in patients within the SAEFRIF trial. Black dots show patients with normal ALT throughout treatment, red points show patients whose ALT rises >50 IU/L during treatment, blue points show patients whose ALT falls from >50 IU/L upon starting treatment. Dotted line on (A) ALT = 50 IU/L.